USFDA approves Novartis Kymriah CAR-T cell therapy
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The integration and transition of the brands are expected to be completed by June 2022.
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
The Toradol tablets, 10 mg brand and generic had U.S. sales of approximately US $ 16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA
The company has posted net profit of Rs.884.08 crores for the Financial Year ended March 31, 2022.
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
Subscribe To Our Newsletter & Stay Updated